ADAM6 and lymphoma: Comparing ALL patients with and without ADAM6 HOM:DEL in the prospective study can evaluate the predictive value of this promising marker, and making stable lymphoid cancer cells carrying such deletion to compare its biological and signaling derangement might explore such novel molecular changes related to ALL.